{"id":"cafaminol","rwe":[{"pmid":"33390094","year":"2022","title":"Shedding light on the bimolecular interactions of Cafaminol and human serum albumin: spectroscopic characterization and in-silico investigation.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"3913153","year":"1985","title":"[Use of the preparation Cafaminol in the treatment of acute rhinitis].","finding":"","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)","studyType":"Clinical Study"},{"pmid":"515164","year":"1979","title":"[Human pharmacologic studies on the biologic availability and resorption of cafaminol (AWD) (proceedings)].","finding":"","journal":"Die Pharmazie","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"rhinoptil","offLabel":[],"synonyms":["cafaminol","methylcoffanolamin","methylcoffanolamine","rhinoptil"],"timeline":[],"brandName":"Rhinoptil","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine Rhinoptil (CAFAMINOL) as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic effect. This process is highly specific and allows the drug to target only certain cells or pathways, minimizing side effects.","oneSentence":"Rhinoptil (CAFAMINOL) is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"Rhinoptil (CAFAMINOL) is a small molecule that binds to a specific receptor or enzyme, altering its activity and leading to a cascade of downstream effects that ultimately produce the desired therapeutic outcome."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cafaminol","title":"Cafaminol","extract":"Cafaminol, also known as methylcoffanolamine, is a vasoconstrictor and anticatarrhal of the methylxanthine family related to caffeine which is used as a nasal decongestant in Germany. It was introduced in 1974 and was still in use as of 2000."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3059","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAFAMINOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Cafaminol","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:07:27.574333","biosimilars":[],"competitors":[],"genericName":"cafaminol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0L1S25NC1L","CHEBI":"CHEBI:135099","INN_ID":"3834","UMLSCUI":"C0054428","ChEMBL_ID":"CHEMBL2104570","PUBCHEM_CID":"35685","MESH_SUPPLEMENTAL_RECORD_UI":"C022126"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2022 Jul","pmid":"33390094","title":"Shedding light on the bimolecular interactions of Cafaminol and human serum albumin: spectroscopic characterization and in-silico investigation.","journal":"Journal of biomolecular structure & dynamics"},{"date":"1985 Oct 15","pmid":"3913153","title":"[Use of the preparation Cafaminol in the treatment of acute rhinitis].","journal":"Wiadomosci lekarskie (Warsaw, Poland : 1960)"},{"date":"1979 May-Jun","pmid":"515164","title":"[Human pharmacologic studies on the biologic availability and resorption of cafaminol (AWD) (proceedings)].","journal":"Die Pharmazie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rhinoptil (CAFAMINOL) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, and bioavailability. Further research is needed to understand its mechanism of action and key safety considerations. As a result, it is difficult to provide a comprehensive summary of this drug.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}